Oviduct derived embryotrophic factor, ETF-3, enhances the development of trophectoderm and the hatching process of treated embryos. Monoclonal anti-ETF-3 antibody that abolishes the embryotrophic activity of ETF-3 recognized a 115 kDa protein from the conditioned medium of immortalized human oviductal cells. Mass spectrometry analysis showed that the protein was complement C3. Western blot analysis using antibody against C3 confirmed the cross-reactivities between anti-C3 antibody with ETF-3 and anti-ETF-3 antibody with C3 and its derivatives, C3b and iC3b. Both derivatives, but not C3, were embryotrophic. iC3b was most efficient in enhancing the development of blastocyst with larger size and higher hatching rate, consistent with previous reported embryotrophic activity of ETF-3. Embryo treated with iC3b contained iC3b immunoreactivity. The oviductal epithelium produced C3 as evidenced by the presence of C3 immunoreactivity and mRNA in human fallopian tube and cultured oviductal cells. Cyclical change in the expression of C3 immunoreactivity and mRNA was also found in mouse oviduct with highest expression at the estrus stage.
Introduction
Since the birth of the first in vitro fertilization-embryo transfer (IVF/ET) baby, researches have been ongoing to optimize the human embryo culture condition. A large proportion of time when embryos are cultured in vitro is when they should be developing in the oviduct in vivo. It is generally accepted that the oviductal microenvironment provides the best support to early embryo development. Oviductal cell coculture, the culture of embryo with oviductal cells, had been shown to improve the success rate in prospective randomized control clinical trials (Yeung et al. 1996b; Yeung et al. 2002) . Our in vitro experiments and others show that human oviductal cell coculture enhances the hatching rate and reduces the fragmentation rate of human embryos (Bongso et al. 1989; Yeung et al. 1992) , increases the blastulation rate and total cell count per blastocyst of mouse embryos (Liu et al. 1995) .
Despite the success of coculture, it is not commonly used in IVF/ET program because of the complexity in its implementation as a routine service. Therefore, sequential culture, the use of different media for culturing embryos at different stages of development, is currently the method of choice for improving the outcome of human IVF (Gardner et al. 1998 ).
However, the culture condition in sequential culture systems is still suboptimal as the development of human embryo in these systems can be further improved by supplementation of granulocyte-macrophage colony-stimulating factor (Sjoblom et al. 1999 ), a cytokine with peak expression during the preimplantation period in human fallopian tube (Zhao and Chegini 1994) . Our unpublished data (Xu JS and Yeung WSB) also show that mouse blastocyst after human oviductal cell coculture in G1.2/G2.2, the most commonly used sequential culture system, have better trophectoderm development and therefore, hatch more often than those cultured in sequential media alone. Thus, the beneficial effect of coculture and sequential culture on embryo development can be merged if the embryotrophic factors from the cocultured cells are known and are supplemented to the sequential culture system.
Human oviductal cell improves the development of mouse embryo in vitro by the production of growth factors, cytokines (e.g. (Yeung et al. 1996a ) and other factors with unknown identities. We have purified 3 embryotrophic fractions termed ETF-1, ETF-2 and ETF-3 from human oviductal cell conditioned medium by various liquid chromatographies (Liu et al. 1995; Liu et al. 1998 ). While ETF-1 and ETF-2 preferentially stimulate the development of inner cell mass, ETF-3 enhances the development of trophectoderm cells, which leads to increase in blastocyst size, hatching and attachment of the hatched blastocyst (Xu et al. 2001) . ETF-3 is most abundant among the three human oviductal cell derived fractions (Liu et al. 1998) .
In this article, we report the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Henzel et al. 1993; O'Connell and Stults 1997; Scheler et al. 1998) and Western blot to identify ETF-3 as a mixture containing complement protein 3 (C3) and its derivative, C3b. We demonstrate that the oviductal 4 epithelium produces the complement protein in a cyclical manner. In the classical immune cascade, C3 is cleaved to C3b and C3a when being activated. C3b is further cleaved to iC3b during inactivation by Factor I in the presence of cofactors, such as membrane cofactor protein (MCP; CD46). In mouse, complement receptor-1-related gene/protein (Crry) served the function of MCP and Decay Accelerating Factor (DAF) (Molina 2002) . In this article, we demonstrate the presence of these molecules in the oviduct/embryo, suggesting that C3b is converted to iC3b, which is the biologically active embryotrophic molecule of ETF-3.
Material and Methods

Production of Anti-ETF-3 Antibody
Anti-ETF-3 monoclonal antibodies were generated by immunizing Balb/cByJ mice subcutaneously with 100 µg affinity-purified ETF proteins isolated from oviductal cell conditioned medium (Liu et al. 1998) in 200 µl of emulsion containing equal volume of PBS and complete Freund adjuvant (Sigma) (Day 0). Booster doses were similarly given in Freund's incomplete adjuvant on day 28 and 42. Three days prior to fusion, a final injection of ETF-3 in sterile PBS was given through tail vein. Fusion of spleen cells and mouse plasmacytoma Sp2/0 cells was carried out as described previously (Luk et al. 1990 ), using polyethyleneglycol PEG4000 (Sigma Co., St. Louis, MO, USA) as fusion agent. Hybridomas were cultivated and selected in RPMI 1640 (Gibco BRL, Paisley, Scotland) standard medium, containing 10% heat-inactivated fetal bovine serum, HAT (0.1 mM hypoxanthine, 0.016 mM thymidine and 0.4 µM aminopterine), 1 mM sodium pyruvate, 100 U penicillin-streptomycin and 5 mM L-glutamine. Screening was performed by enzyme immunoassay 10-12 days after fusion against purified ETF-3. Positive hybridomas were cloned by limiting dilution and subsequently mAbs were produced in serum-free medium or ascites fluids.
Antibodies clone 14 (IgG….) were purified by affinity chromatography using HiTrap Protein G Sepharose (Amersham Pharmacia Biotech) and concentrated by the Centricon-30 (Amicon, Inc., Beverly, CA). The immunoreactivity of the purified monoclonal antibody was confirmed by western blot analysis of three different batches of ETF-3.
Protein-G purification of ETF-3
The conditioned media derived from immortalized oviductal cells, OE-E6/E7, were fractionated as previously described (Lee et al. 2001) . Briefly, the cells were grown in Dulbecco modified Eagle medium/Ham F12 (DMEM/F12) supplemented with 0.3% (w/v) BSA (Sigma, St. Louis, MO). Fifty milliliters of oviductal cell conditioned medium were passed through a concanavalin-A affinity column using a fast-performance liquid chromatographic system (Amersham Pharmacia Biotech, Uppsala, Sweden). The column was washed with a start buffer (20 mM Tris, 0.5 M NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , and 1 mM MnCl 2 , pH 7.4) at a flow rate of 0.3 ml/min for 30 min to remove unbound molecules. The bound glycoproteins were eluted with the same buffer containing 0.3 M α-D-methylglucoside at a flow rate of 0.3 ml/min. The eluate was dialyzed against PBS in porous tubing with molecular size cutoff of 12-14 kDa (Spectrum Laboratories, Inc. Rancho Dominguez, CA).
Two hundred microgram of purified monoclonal antibody (clone 14) was added to the dialysed concanavalin-A eluate and incubated overnight at 4 o C on a rocking platform. The mixture was allowed to pass through a 5-ml HiTrap Protein G column (Amersham Pharmacia Biotech) and washed with 20 mM sodium phosphate buffer, pH 7.0. The bound antibody-antigen complex was eluted with 0.1 M glycine-HCl buffer, pH 2.7 and collected in neutralizing 1 M Tris-HCl buffer, pH 9.0. The purified fraction was concentrated by the Centricon-30 (Amicon, Inc., Beverly, CA). To confirm that the purity of protein-G purified ETF-3, Western blot analysis of the purified ETF-3 was performed using purified clone 14 antibody (1:100) and anti-mouse IgG antiserum conjugated with horseradish peroxidase
(1:5000). The signal was visualized by enhanced chemiluminescence (ECL) according to the manufacturer's recommendations (Santa Cruz, CA, USA).
Two-dimensional gel electrophoresis and silver staining
About 10 µg of affinity purified ETF-3 was reconstituted in 250 µl of rehydration Staining was stopped by rinsing the gel with 5% acetic acid.
MALDI-TOF peptide mass fingerprint analysis
The 115-kDa protein band from one-dimensional SDS-PAGE was used for mass spectrometry analysis. The excised gel was sliced into 1x1 mm pieces and equilibrated with 0.5 ml of 50 mM NH 4 HCO 3 for 10 min with 700 rpm agitation at room temperature. 
Western Blot Analysis using anti-C3 and purified clone-14 antibody
To confirm that ETF-3 secreted from OE-E6/E7 cells was C3 and that the monoclonal antibody raised against ETF-3 also recognized C3, different C3 fragments (C3, C3b and iC3b) purified from human serum (Calbiochem, CA, USA), concanavalin-A eluted fraction and ETF-3 derived from OE-E6/E7 after Centricon-100 centrifugation were separated by 8% SDS-PAGE. The proteins were then transferred to PVDF membrane, on which Western blot were performed using either goat anti-human C3 antibody (1:20,000 dilution) or clone-14
(1:100 dilution) in blocking solution containing 5% skim milk in PBS with 0. Table 1 ). The PCR products were analyzed in a 2% agarose gel (Gibco GRL).
RT-PCR for human C3 and factor I expression
C3 protein and mRNA expression in mouse oviducts in estrous cycle
Sexually mature (6-to 8-week old) MF1 female mice were used. The estrous cycle was determined by vaginal smear. The protein expression of C3 in MF1 mouse oviducts at different estrus cycles, pro-estrus (P), estrus (E), met-estrus (M) and di-estrus (D) was studied by immunohistochemical staining described above using polyclonal antibody against the β-chain of C3 (sc-14612, Santa Cruz, CA). The antibody was omitted in the negative control.
Semi-quantitative RT-PCR was used to determine the relative changes of C3 mRNA transcripts in mouse oviducts in the estrus cycles. Mosue C3 specific primers (Table 1) 
Messenger RNA expression of complement binding proteins in mouse embryos
The expression of cofactors/receptor possibly involved in the conversion of C3b to iC3b was studied. In vivo developed mouse embryos at the 1-cell, 2-cell, 4-cell, 8-cell/morula, and blastocyst stages were flushed from either oviducts or uteri at 22-24, 42-46, 67-71, 88-92, and 100-104 h post-hCG, respectively. Two-step RT-PCR was used to determine the complement receptor-1-related gene/protein (Crry), CD11b, CD18, decay accelerating factor (DAF; CD55) mRNA transcripts in these embryos. Gene-specific primers were designed and listed in Table 1 . Briefly, mRNA of embryos was isolated using Dynabeads mRNA Direct Kit (Dynal AS) as described (Lee et al. 2003 ) and subjected to two step RT-PCR analysis as described above.
Results
Identification of ETF-3
In order to purify ETF-3 to homogeneity for identification, monoclonal antibodies against ETF-3 was raised. The antiserum of the mouse from which the hybridoma clones were raised nullified the activity of ETF-3 on blastulation and hatching of mouse embryos (Lee et al., 2003) . The antiserum also bound to the epithelial cells of human fallopian tube and to the blastomeres of ETF-3 treated mouse embryos (Lee et al., 2003) . Monoclonal antibody from hybridoma (clone-14) abolished the embryotrophic effect of ETF-3 (Fig. 1 ).
Western blot analysis showed the presence of an extra 115 kDa protein (PG-115, lane A, antibody alone (lane B, Fig. 2 ). In two-dimensional gel electrophoresis, the protein appeared as dots with same size but with slightly different pI ranging from 6-7 (data not shown). This was consistent with our previous conclusion that ETF-3 was glycoprotein in nature (Liu et al. 1998 ). Database search showed that the peptide mass fingerprint from MALDI-TOF mass spectrum of PG-115 after in-gel tryptic digestion was complement C3 precursor (Table 2 ).
Fig . 3A shows the protein patterns of commercially available C3 and its fragments, C3b and iC3b. Polyclonal antibody against C3 recognized all the subunits in C3 and its fragments (Fig. 3C) . Anti-ETF-3 antibody (clone-14) reacted with the 115 kDa α-chain of C3 (α-115) and the 106 kDa α'-chain of C3b (α'-106), and the 40 kDa α-chain of iC3b (α-40) (Fig. 3B) , indicating that the binding epitope of the antibody was in the α-40 of C3 fragments.
Anti-C3 polyclonal antibody detected the presence of C3 fragments in purified and partially purified ETF-3 (concanavalin-A bound fraction of OE-E6/E7 conditioned medium) with sizes of 115, 106, 75 and 40 kDa (Fig. 3F) . Mass spectrometry analysis of the 115, 106
and 75 kDa bands confirmed their identities as C3 precursor (Data not shown). A band of about 190 kDa was also found in purified ETF-3 and partially purified samples. This possibly represented C3 precursor in the lysate of OE-E6/E7 that had been concentrated after purification. C3 precursor is a single chain molecule with size about 180 kDa. It is cleaved into the α and β chains of C3 during post-translational modification. Anti-ETF-3 antibody recognized the 115, 106, and 40 kDa bands of purified and partially purified ETF-3 (Fig. 3E ).
Embryotrophic activity of C3 and its fragments
The development of mouse embryo in medium alone and medium supplemented with different C3 fragments is shown in Table 3 . The rate of embryo development was based on the number of 2-cell embryos after 24 hours of culture. The embryos incubated with iC3b for 4 days had significantly more expanded blastocysts and higher hatching rate (p<0.05) when compared with those cultured in medium alone and media supplemented with other C3
fragments. The size of the expanded blastocysts in the iC3b group as determined by the area of the expanded blastocyst was also significantly larger than the other groups (p<0.05). Both C3b and iC3b stimulated hatching of the treated embryo. Result of immunostaining of iC3b treated embryos at different stages of development using purified clone-14 antibody are shown in Fig. 4 . iC3b bound to the mouse embryos starting from 2-cell stage. The immunoreactivities persist at all developmental stages, from 2-cell stage to blastocyst stage.
Medium alone cultured embryo did not possess the immunoreactivity.
Protein and mRNA expression of oviduct and oviductal cells
C3 immunoreactivity was localized to the epithelial lining of human fallopian tube obtained from patients admitted for tubal ligation or hysterectomy due to uterine fibromyoma (Fig. 5) . After pre-absorption of the anti-C3 antibody with ETF-3 or iC3b, no signal was found in the sections. Immortalized human oviductal cells, OE-E6/E7 possessed C3 immunoreactive signal, which was absent when anti-C3 antibody pre-absorbed with ETF-3 was used (Fig. 6 ). Factor I was localized to the epithelial lining of the human oviduct and no signal was obtained in the section when anti-factor I antibody was preabsorbed with factor I (Fig. 7) .
The expression of human C3 mRNA (972 bp) and human factor I (722 bp) were detected in two primary oviductal cell samples, OE-E6/E7 cells at passages 14 and 25, oviductal epithelium tissue from 2 patients, SKOV-3 and human liver tissue (Fig. 8) . No such mRNA expression was found in CHO-K1 cell lines.
Positive staining of C3 was found in the epithelial lining of mouse oviduct at different stages ( Fig. 9 A-D) . The C3 immunoreactivity was strong during estrus and metestrus when compared to that diestrus and proestrus. The change in the intensity of immunoreactivity was positively correlated with the mRNA expression levels (Fig. 10) . C3 mRNA expression was highest during estrus and lowest during diestrus. Statistical significant difference (p<0.05) was found between these two stages.
Crry, CR3 and DAF expression in mouse preimplantation embryo
The expression of mouse Crry, CD11b (α M ) and CD18 (β 2 ) of CR3 and DAF mRNA was determined in the preimplantation mouse embryo at different developmental stages (Fig. 11 ).
Crry (520 bp) and DAF (563 bp) were constitutively expressed throughout preimplantation development. The α M (498 bp) and β 2 (282 bp) of CR3 were expressed in mouse embryo, but the expression of α M was absent at the 3-4 cell and morula stages while that of β 2 was present from 2-cell onwards. All the transcripts were present in mouse liver (positive control).
Discussion
We describe here the identification of ETF-3 as complement C3 and that its derivatives are embryotrophic. Our previous data showed that the ETF-3 enhanced the development of trophectoderm and hatching of the treated embryos (Xu et al. 2001 ). The beneficial effect of ETF-3 on mouse embryo development is also seen when it is supplemented to G1.2/G2.2 sequential embryo culture system (Xu J.S. and Yeung W.S.B. unpublished observation).
Monoclonal antibody that abolishes the embryotrophic effect of ETF-3 recognizes a 115 kDa protein with identity confirmed by MALDI-TOF mass spectrometer to be complement C3.
This is verified by the cross-reactivities between anti-C3 antibody with ETF-3 and anti-ETF-3
antibody with C3 and its derivatives.
Previous study demonstrated the presence of C3 protein or its derivatives in human oviduct (Tauber et al. 1985) . However, the cellular location of the protein has not been studied. The present study localized C3 immunoreactivity to the cytoplasm of the epithelial lining of human oviduct. The lack of staining on oviduct sections using anti-C3 antibody preabsorbed with ETF-3 and iC3b confirms that the immunoreactivity is due to at least a et al. 2002) and rat (Puy et al. 1993 ) and the higher biosynthetic activity of C3 in human endometrium in the luteal phase than that in the proliferative phase (Hasty et al. 1994) .
Therefore, it is likely that the observed embryotrophic phenomenon of ETF-3 is of physiological importance (or function). We hypothesize that the oviduct of human and mouse secretes C3 and its derivatives to enhance the development of early embryo. found, which could be due to its genuine absence or presence at concentration below the sensitivity of detection. In any cases, iC3b cannot be a major component in the ETF-3 preparation. ETF-3 improves mouse embryo development in terms of size, blastulation and hatching rate (Xu et al. 2001) , which is similar to iC3b. The reason that C3b alone only increase the hatching rate could possibly be due to high concentration of C3b used in the present experiment. Previous study has also demonstrated that saturating doses (>10uM) of dimeric C3b can inhibit the sperm-oocyte interaction (Anderson et al. 1993) . Dose responses of C3 and its fragments on the development of mouse embryo are being studied in this laboratory.
Although C3 and C3b are the major constituents of ETF-3, iC3b is more potent than C3b in stimulating mouse embryo development, and C3 is not embryotrophic. In the activation of complement cascade, factor I in the presence of cofactors (MCP, Factor H, CR1) cleaves C3b into iC3b and C3f. Factor I mRNA has been detected in rat uterus (Schlaf et al. 1999) . In the present study, we demonstrated the de novo synthesis of factor I in human oviduct and cultured oviductal cells, suggesting that the oviduct produces factor I, which together with membrane bound cofactors on mouse embryo, e.g. Crry, cleave C3b into iC3b. The observation that exogenous iC3b alone can stimulate embryo development to the greatest extent indicates that the molecule is the actual active form in stimulating embryo development.
The presence of iC3b immunoreactivity in the embryo after treatment supports this hypothesis.
The lack of factor I in embryo culture medium may explain the low embryotrophic activity of exogenous C3b when being used alone in culturing embryo.
To test this hypothesis, expression of membrane bound cofactors and iC3b binding protein on mouse embryo were studied. Our data demonstrated that mouse Crry transcript were present in embryos from 1-cell to blastocyst stage. In mouse, Crry serves as a cofactor for factor I-mediated cleavage of C3b (Kim et al. 1995) . Complement receptor 3 (CR3; α M β 2 ; CD11b/CD18; Mac-1) is a member of the β 2 integrin family with iC3b binding activity (Morley and Walport 2000b) . Although β 2 transcript is present from the 2 cell to blastocyst stages, the α M transcripts were present only from 1-cell to 3-4 cell stages, indicating that CR3 may be functional only in early cleavage stages. This may account for some embryotrophic activity of ETF-3 observed at these stages (Xu et al. 2001) . However, the maximal efficiency of ETF-3 treatment is between 3-4 cells and blastocyst stage (Xu et al. 2001) . Therefore, it is unclear whether the embryotrophic effect of iC3b acts via interaction with β2 integrins at later stages.
The I domain that appears in the α M subunit but not in other integrins is the ligand recognition site for iC3b (Diamond et al. 1993; Shimaoka et al. 2002) . The I domain like region of the β 2 chain is also involved in binding to iC3b (Goodman and Bajt 1996) .
Complement receptor 3 binds to the α-40 chain (aa 1383-1403) of iC3b (Morley and Walport 2000a). Interestingly, the binding epitope of the monoclonal antibody used in the present study with neutralization effect on ETF-3 embryotrophic activity also lies in the α-40 chain.
The possible presence of isoforms of CR3 to mediate the embryotrophic action of iC3b at later stages of preimplantation embryo development cannot be excluded.
Integrins involve in cell-cell and cell-matrix interactions, cell signaling and survival (Bloor et al. 2002) . Previous studies demonstrated that β1 and β3 subunits were constitutively expressed throughout preimplantation development in mouse (Sutherland et al. 1993 ) and human with expression localized to trophectoderm cells (Bloor et al. 2002) . Although β 2 integrins leukocyte restricted (Kolanus et al. 1996) , the presence of its member, CR3, in oocyte is controversial; CR3 was reported to be present in human oocyte in one study (Anderson et al. 1993 ) but could not be substantiated in another study (Taylor and Johnson 1996) .
A recent study on the role of complement in systemic tolerance after injection of antigen into the eye demonstrated that the binding of iC3b to CR3 on antigen-presenting cells induced the production of transforming growth factor-β2 (TGFβ2) (Sohn et al. 2003) . The presence of TGFβ and its receptors in preimplantation embryo and oviduct of mouse (Chow et al. 2001) supports a role of TGFβ during preimplantation embryo development. This is consistent with the observation that injection of anti-TGFβ2 antibody into the blastocoel markedly reduced the implantation rate of mouse embryo (Slager et al. 1993) . ETF-3 increases the implantation rate of mouse embryo (Liu et al. 1998) . The relationship between iC3b, CR3 and TGFβ in mouse preimplantation embryo is being investigated in this laboratory.
In conclusion, we have demonstrated a novel function of C3 in reproduction. The oviduct produces C3/C3b, which is converted to iC3b. iC3b stimulates the development of mouse blastocyst in terms of size and hatching. This is consistent with our previous observations of increased hatching rate of human embryos after oviductal cell coculture (Yeung et al. 1992 ) and improved trophectoderm development of mouse embryos after ETF-3 treatment (Xu et al. 2001) . The detailed regulation of C3 production and the mechanism of action of the iC3b on embryo development await further investigation. whereas no such band was found in purified antibody alone (B). immunoreactivity is localized to the epithelial lining of the human oviduct (B). The signal for C3 immunoreactivity is absent after the antibody is preabsorbed with ETF-3 (E) and iC3b (H).
Bar: 20µm showing nuclei stained with propidium iodide (red). Factor I immunoreactivity is localized to the epithelial lining of the human oviduct (A). The signal for factor I immunoreactivity is absent after the antibody is preabsorbed with factor I (C). embryo at 1-cell (1), 2-cell (2), 3-4 cell (3), morula (4), blastocyst (5), mouse liver (6) and dH 2 O control (7). Ethidium bromide-stained PCR products of Crry (520 bp), DAF (563bp) and GAPDH (452 bp) were present in all stages of embryos. CD11b (498bp) was absent in 1-cell embryos whereas CD18 (282bp) was only present in 1-cell to 3-4 cell embryos. GAPDH, 452bp
